CoronaryAtlas logo
CoronaryAtlas
Midregional Pro-Adrenomedullin
Pathway / Off-pathway / systemic markers

Midregional Pro-Adrenomedullin

ADMpeptide

MR-proADM reflects endothelial dysfunction, hemodynamic stress, and renal complications; predicts MI and heart failure outcomes.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleEndothelial protection; hemodynamic/renal stress marker; prognostic predictor.
Also acts inEndothelial activation/erosion
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000148926

Type I vs Type II discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — confounder / Type-II
33
A — assay feasibility
66
E — evidence strength
50
T1DI (composite)
14
Specificity differential (R−C)-18.3
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencymag 1
7high-demand / peri-operative stressn/a
Coverage: 1/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 1 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade

Literature evidence(7)